Chronic hepatitis B affects about 296 million people worldwide. Prevalence ranges from 5% in the Western Pacific to 0.8% in Europe. In the US, an estimated 862,000 people live with chronic HBV, and about 21,600 new infections occur each year.
Key Takeaways
- Globally, an estimated 296 million people were living with chronic Hepatitis B virus (HBV) infection in 2019, with regional prevalence varying from 5% in the Western Pacific to 0.8% in Europe
- In 2022, the global prevalence of chronic HBV infection was 3.88% among adults aged 20-69 years, equating to approximately 254 million people
- The United States had an estimated 862,000 persons living with chronic HBV infection in 2018, with 21,600 new infections annually
- Global hepatitis B vaccination coverage reached 85% for DTP3 in 2022
- Infant HBV vaccination prevents 75-95% of perinatal transmissions
- Three-dose HepB vaccine efficacy 95% in preventing chronic infection in infants
- Chronic HBV infection develops in 90% of infants infected perinatally vs 5% adults
- Acute HBV symptoms occur in 30-50% of infected adults, including fatigue, jaundice, and abdominal pain lasting 1-3 months
- HBsAg positivity for >6 months indicates chronic infection in 90% of perinatally infected children
- Globally, 96% of HBV perinatal transmissions occur in high endemicity areas
- Mother-to-child transmission accounts for >90% of chronic infections in high-prevalence regions like Asia and Africa
- In the US, injection drug use caused 23% of acute HBV cases in 2018
- Tenofovir suppresses HBV DNA to <20 IU/mL in 95% patients at 48 weeks
- Entecavir achieves HBeAg seroconversion in 20-30% over 5 years
- Peg-IFN alfa induces HBsAg loss in 3-7% HBeAg-positive patients
In 2019, about 296 million people lived with chronic hepatitis B, causing most deaths worldwide.
Related reading
01 · Category
Prevalence and Incidence29 stats
01
Globally, an estimated 296 million people were living with chronic Hepatitis B virus (HBV) infection in 2019, with regional prevalence varying from 5% in the Western Pacific to 0.8% in Europe
02
In 2022, the global prevalence of chronic HBV infection was 3.88% among adults aged 20-69 years, equating to approximately 254 million people
03
The United States had an estimated 862,000 persons living with chronic HBV infection in 2018, with 21,600 new infections annually
04
In sub-Saharan Africa, HBV prevalence exceeds 8% in the general population, with East Africa at 4.3% and West Africa at 9.5%
05
Among HBsAg-positive pregnant women in China, the prevalence was 5.26% in 2018, down from 7.18% in 1992 due to vaccination programs
06
In 2019, 14.4 million people in Africa were living with chronic HBV, representing 4.9% prevalence
07
The age-standardized incidence rate of HBV in India was 1.62 per 100,000 in 2017
08
In Mongolia, HBV prevalence among adults is 10.2%, one of the highest globally
09
US acute HBV incidence declined 61% from 2009-2018, from 1.0 to 0.4 cases per 100,000 population
10
In Vietnam, chronic HBV prevalence is 6.9% among those aged 25+
11
Globally, 820,000 HBV-related deaths occurred in 2019, mostly from cirrhosis and hepatocellular carcinoma (HCC)
12
In Pakistan, HBV prevalence is 2.5% nationally, but 7.2% in Khyber Pakhtunkhwa province
13
Egypt's HBV prevalence dropped to 1.3% by 2018 from 6.7% in 1993 due to interventions
14
In 2020, 257 million people had chronic HBV in the WHO Western Pacific Region
15
Taiwan's chronic HBV carrier rate fell to 1.2% in children born after 1992 vaccination
16
In Brazil, HBV prevalence is 0.65% in blood donors, higher in Amazon regions at 2.5%
17
Global HBV incidence was 1.5 million new infections in 2019
18
In South Korea, seroprevalence decreased to 2.2% in 2018 from 4.6% in 2006
19
Nigeria has 20 million chronic HBV carriers, prevalence 9.5%
20
In 2016, Europe's HBV prevalence was 0.9%, with 1.2 million chronic cases
21
Alaska Natives had 6.6% HBV prevalence pre-vaccination, now <1%
22
In 2021, China's HBV infection rate in under-5s was 0.32%
23
Global pooled HBV prevalence in general population is 3.61% (95% CI 3.36-3.86%)
24
Iran's national HBV prevalence is 2.14%
25
In 2019, Southeast Asia had 80 million chronic HBV cases, prevalence 3.4%
26
US chronic HBV prevalence is 0.3% overall, but 5-10% in Asian Americans
27
Cameroon has 8.6% HBV prevalence, highest in Central Africa
28
In 2020, Eastern Mediterranean Region had 14.5 million chronic HBV, prevalence 2.2%
29
Japan's HBV prevalence is 0.7% in adults
Interpretation
Prevalence and Incidence Interpretation
Hepatitis B is a staggering global game of viral hide-and-seek, where vaccination plays the brilliant seeker, yet in many regions, the virus remains distressingly easy to find.
02 · Category
Prevention and Vaccination30 stats
01
Global hepatitis B vaccination coverage reached 85% for DTP3 in 2022
02
Infant HBV vaccination prevents 75-95% of perinatal transmissions
03
Three-dose HepB vaccine efficacy 95% in preventing chronic infection in infants
04
Birth-dose vaccination coverage 42% globally in 2022
05
Taiwan's universal vaccination reduced HCC in children by 75% since 1984
06
Vaccine-induced anti-HBs persists >10 years in 70-90% children
07
HBIG + vaccine post-exposure prevents 75-95% infection in infants of carriers
08
Universal infant vaccination averted 310 million chronic infections 1990-2020
09
US adolescent catch-up vaccination coverage 91.2% for >=1 dose (2021)
10
Recombinant HepB vaccine seroprotection 90-100% after 3 doses in adults
11
Screening pregnant women identifies 95% HBsAg-positive for intervention
12
Booster doses needed in 10-20% immunocompromised after 5 years
13
China's EPI program vaccinated 99% newborns by 2019, prevalence <1%
14
Healthcare worker vaccination coverage 70% globally, gaps in low-income countries
15
Heplisav-B (adjuvanted) seroprotection 90-95% in 2 doses vs 70% Engerix
16
Gambia Hepatitis Intervention Study: vaccination reduced chronic carriage 90%
17
Post-exposure prophylaxis success 90% if within 24 hours needlestick
18
WHO goal: 90% birth dose by 2030 to eliminate HBV as public health threat
19
Alaska Native program: prevalence fell from 6% to 0.1% post-vaccination
20
Dialysis patient vaccination response 50-70%, revaccination improves to 90%
21
Safe injection practices prevent 50% of new HBV infections in healthcare
22
MSM vaccination coverage 50-60% in US, targeted campaigns needed
23
Genotype non-response rare (<5%) to standard vaccines
24
Household contacts of carriers: 70% protection with vaccine + HBIG
25
Global DTP3-HepB3 coverage 83% (2021)
26
Infant vaccination + screening reduced US perinatal cases 90% since 1990
27
Obese adults vaccine response 30-50% lower, high-dose improves to 80%
28
Vietnam expanded program: under-5 prevalence 1% from 10% pre-1992
29
Blood donor screening prevents 99.9% transfusion-transmitted HBV
30
Therapeutic vaccines in trials: HBsAg reduction 20-50% in responders
Interpretation
Prevention and Vaccination Interpretation
The global fight against hepatitis B is a stunningly successful yet frustratingly incomplete masterpiece, showing us that with vaccines we can carve future cases from a mountain of data, yet we keep leaving the chisel—the critical birth dose—on the bench for over half the world's newborns.
03 · Category
Symptoms and Diagnosis30 stats
01
Chronic HBV infection develops in 90% of infants infected perinatally vs 5% adults
02
Acute HBV symptoms occur in 30-50% of infected adults, including fatigue, jaundice, and abdominal pain lasting 1-3 months
03
HBsAg positivity for >6 months indicates chronic infection in 90% of perinatally infected children
04
Liver cirrhosis develops in 15-25% of chronic HBV carriers over 20-30 years
05
Sensitivity of HBsAg rapid diagnostic tests is 92-99% in high viral loads
06
HBV DNA PCR quantification has lower limit of detection 10-20 IU/mL, essential for monitoring
07
Anti-HBc IgM indicates acute infection with 95% specificity
08
HCC risk is 100-fold higher in chronic HBV vs general population
09
ALT elevation >2x ULN occurs in 20-30% of immune active chronic phase patients
10
Liver biopsy shows inflammation in 70% of HBeAg-positive carriers
11
Ultrasound detects HCC in 70-90% of cases in surveillance programs
12
FibroScan accuracy for fibrosis staging is 85-90% vs biopsy
13
Extrahepatic manifestations like polyarteritis nodosa occur in 1-5% chronic HBV
14
HBeAg seroconversion associates with ALT flare in 20-40% cases
15
Asymptomatic chronic carriage in 70-80% of infected individuals lifelong
16
HBV genotype A linked to higher rates of HBeAg seroconversion (15%/year)
17
AFP levels >400 ng/mL in 60-80% HCC cases with HBV
18
Acute HBV incubation period averages 90 days (30-180 range)
19
Renal biopsy in HBV glomerulonephritis shows deposits in 80% membranous cases
20
Transient elastography correlates 90% with fibrosis scores in HBV
21
Cryoglobulinemia in 5-15% chronic HBV with vasculitis symptoms
22
Immune tolerant phase shows normal ALT in 95% young carriers
23
HBV DNA >2,000 IU/mL with ALT >2x ULN indicates treatment need in HBeAg-negative
24
Jaundice present in 40% acute adult HBV infections
25
HBsAg loss occurs in 0.5-2% per year naturally in chronic HBV
26
Liver stiffness >12 kPa on FibroScan predicts cirrhosis with 90% accuracy
27
Fulminant hepatitis in <1% acute HBV, mortality 60-90% without transplant
28
Anti-HBs >10 mIU/mL indicates immunity post-vaccination or resolved infection
29
HBV core promoter mutations in 30-50% HCC cases
30
Fatigue reported in 60% chronic HBV patients regardless of ALT
Interpretation
Symptoms and Diagnosis Interpretation
Your liver's tolerance for this virus is like a fussy bouncer, letting 90% of infected infants become lifelong residents while turning away most adults, only to watch that stubborn 5% adult crowd slowly, over decades, cause havoc where cirrhosis, cancer, and fatigue become the unwelcome fixtures for many.
More related reading
04 · Category
Transmission and Risk Factors29 stats
01
Globally, 96% of HBV perinatal transmissions occur in high endemicity areas
02
Mother-to-child transmission accounts for >90% of chronic infections in high-prevalence regions like Asia and Africa
03
In the US, injection drug use caused 23% of acute HBV cases in 2018
04
Unsafe injections cause 1.7 million new HBV infections annually worldwide
05
Heterosexual transmission accounts for 12% of acute HBV in the US (2018)
06
HBV transmission risk from HBeAg-positive mother without intervention is 70-90% at birth
07
In endemic areas, horizontal transmission in early childhood contributes 30-50% of chronic infections
08
Blood transfusion transmission risk pre-screening was 1:63, now <1:1 million with NAT testing
09
MSM account for 4% of acute HBV cases in US, but higher in outbreaks
10
HBV DNA levels >10^6 IU/mL in mother increase MTCT risk to 40% even with HBIG
11
Occupational exposure risk for healthcare workers is 2-5% without vaccination
12
In Africa, traditional practices like scarification transmit HBV to 20-30% of children
13
Household contact transmission risk is 3-6 times higher for chronic carriers
14
Dialysis patients have 10-20 times higher HBV prevalence due to nosocomial transmission
15
Perinatal transmission reduced by 75% with antiviral prophylaxis in high viral load mothers
16
In US, 25% of acute cases (2018) had unknown risk factor
17
HBV genotype D is most common in Middle East (80%), associated with horizontal transmission
18
Prison populations have 5-10% HBV prevalence from injection drug use and tattoos
19
Sexual transmission risk per act is 1-30% for unvaccinated partners of carriers
20
In China, early childhood horizontal transmission was 40% pre-vaccination
21
HBV and HIV co-infection increases transmission risk 5-6 fold
22
Nosocomial transmission in developing countries causes 10-20% of infections
23
HBsAg screening reduces transfusion transmission to 1:2 million
24
In Mongolia, 60% of chronic infections from perinatal transmission
25
Incarcerated populations in US have HBV prevalence 3-5 times general population
26
HBV transmission via needlestick injury is 6-30%
27
In Vietnam, 70% chronic cases from perinatal or early childhood exposure
28
About 50% of chronic HBV infections worldwide result from mother-to-child transmission
29
HBV genotype C prevalent in Pacific (50%), linked to higher MTCT rates
Interpretation
Transmission and Risk Factors Interpretation
While a resilient virus exploits humanity's most tender moments and systemic failings—from the cradle where it claims half of all chronic carriers worldwide to the needle and the hospital ward—our most powerful weapons remain stunningly simple: vaccination, screening, and the antiviral guard that can break a 90% maternal transmission curse.
05 · Category
Treatment and Management29 stats
01
Tenofovir suppresses HBV DNA to <20 IU/mL in 95% patients at 48 weeks
02
Entecavir achieves HBeAg seroconversion in 20-30% over 5 years
03
Peg-IFN alfa induces HBsAg loss in 3-7% HBeAg-positive patients
04
Lamivudine resistance develops in 70% after 5 years monotherapy
05
TDF reduces HCC risk by 50% in high-risk chronic HBV cirrhotics
06
Nucleos(t)ide analogues suppress HBV in 98% without seroconversion usually
07
Telbivudine HBeAg seroconversion rate 25% at 1 year vs 18% entecavir
08
Adefovir resistance 29% at 5 years in lamivudine failures
09
IFN therapy contraindicated in decompensated cirrhosis (mortality 20-30%)
10
Baraclude (entecavir) normalizes ALT in 68% at 48 weeks
11
Tenofovir alafenamide has bone density loss <1% vs 2-3% TDF
12
Liver transplant 5-year survival 80% for HBV-HCC
13
Emtricitabine/TDF combo suppresses 93% HBV DNA <400 copies/mL at 96 weeks
14
PegIFN + adefovir HBsAg decline 1.1 log IU/mL faster than monotherapy
15
Long-term NUC therapy HCC incidence 3.3% over 5 years in cirrhotics
16
Vemlidy (TAF) renal safety superior, eGFR decline 0.4 mL/min vs 2.5 TDF
17
HBeAg-negative patients: entecavir virologic response 90% at 2 years
18
Interferon relapse rate 80-90% post-48 weeks in responders
19
TDF in pregnancy reduces MTCT to <5% in high-load mothers
20
Functional cure (HBsAg loss) in 1-3% annually on NUCs long-term
21
ADV monotherapy ALT normalization 48-72% at 48 weeks
22
Decompensated HBV: lamivudine survival benefit 79% vs 41% placebo at 1 year
23
Newer agents like besifovir resistance <1% at 96 weeks
24
PegIFN in genotype D: HBeAg loss 29% vs 12% genotype A
25
NUC switch to PegIFN: HBsAg loss 9% vs 0% continuation
26
TDF + PegIFN combo HBeAg seroconversion 35% at 48 weeks
27
Cirrhosis regression in 50-70% on long-term antiviral therapy
28
HBV-HDV co-infection: pegIFN response 25-40% HBsAg loss
29
Kidney transplant HBV recurrence <5% with prophylaxis
Interpretation
Treatment and Management Interpretation
The landscape of hepatitis B therapy is a strategic chess game where we can now reliably control the viral army in nearly all patients, but achieving the ultimate checkmate of a functional cure remains a rare and hard-won victory, constantly balanced against the risks of resistance, side effects, and the relentless shadow of liver cancer.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priyanka Sharma. (2026, February 13). Hep B Statistics. Gitnux. https://gitnux.org/hep-b-statistics
MLA
Priyanka Sharma. "Hep B Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hep-b-statistics.
Chicago
Priyanka Sharma. 2026. "Hep B Statistics." Gitnux. https://gitnux.org/hep-b-statistics.
Sources & references
9 datasets cited across this report · attribution is report-level